Brain penetration, target engagement, and disposition of the blood-brain barrier-crossing bispecific antibody antagonist of metabotropic glutamate receptor type 1

From National Research Council Canada

DOI	Resolve DOI: https://doi.org/10.1096/fj.201500078
Author	Search for: Webster, Carl I.; Search for: Caram-Salas, Nadia¹; Search for: Haqqani, Arsalan S.¹; Search for: Thom, George; Search for: Brown, Lee; Search for: Rennie, Kerry¹; Search for: Yogi, Alvaro¹; Search for: Costain, Willard¹; Search for: Brunette, Eric¹; Search for: Stanimirovic, Danica B.¹
Name affiliation	National Research Council of Canada. Human Health Therapeutics
Format	Text, Article
Journal title	The FASEB Journal
ISSN	0892-6638 1530-6860
Volume	30
Issue	5
Pages	1927–1940
Subject	Pain; Receptor-mediated transcytosis; Brain endothelial cells; Mass spectrometry
Abstract	Receptor mediated transcytosis harnessing the cellular uptake and transport of natural ligands across the blood–brain barrier (BBB) has been identified as a means for antibody delivery to the CNS. In this study, we characterized bispecific antibodies in which a BBB-crossing antibody fragment FC5 was used as a BBB carrier. Cargo antibodies were either a high-affinity, selective antibody antagonist of the metabotropic glutamate receptor-1 (BBB-mGluR1), a widely abundant CNS target, or an IgG that does not bind the CNS target (BBB-NiP). Both BBB-NiP and BBB-mGluR1 demonstrated a similar 20-fold enhanced rate of transcytosis across an in vitro BBB model compared with mGluR1 IgG fused to a control antibody fragment. All 3 bispecific antibodies exhibited identical pharmacokinetics in vivo. Comparative assessment of BBB-NiP and BBB-mGluR1 revealed that, whereas their serum pharmacokinetics and BBB penetration were identical, their central disposition (brain levels) and elimination (cerebrospinal fluid levels) were widely different, due to central target-mediated removal of the mGluR1-engaging antibody. Central mGluR1 target engagement after systemic administration was demonstrated by a dose-dependent inhibition of mGluR-1-mediated thermal hyperalgesia and by colocalization of the antibody with thalamic neurons involved in mGluR1-mediated pain processing. We demonstrate the feasibility of targeting central G-protein-coupled receptors using a BBB-crossing bispecific antibody approach and emerging principles that govern brain distribution and disposition of these antibodies. These data will be important for designing safe and selective CNS antibody therapeutics.
Publication date	2016-02-02
Publisher	Federation of American Societies for Experimental Biology
Language	English
Peer reviewed	Yes
NPARC number	23000385
Export citation	Export as RIS
Report a correction	Report a correction
Record identifier	73a5d42c-7e5f-4e65-836d-407585a2631b
Record created	2016-07-12
Record modified	2020-03-16

Report a problem on this page

Date modified:: 2021-06-15